ELEANOR COLLINSON

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th House and Senate Appropriations The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 553, Endocrine Disruptor Screening Enhancement Act of 2011. The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy, In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report, The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314, The Consumer Product Safety Commission Improvement Act, The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354, Breast Cancer and Environmental Research Act of 2008, This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th House and Senate Appropriations The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 553, Endocrine Disruptor Screening Enhancement Act of 2011. The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy, In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report, The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314, The Consumer Product Safety Commission Improvement Act, The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354, Breast Cancer and Environmental Research Act of 2008, This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process. S.3209, the Safe Chemicals Act of 2010 (House bill not yet introduced). The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process. S.3209, the Safe Chemicals Act of 2010 (House bill not yet introduced). The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process. S.3209, the Safe Chemicals Act of 2010 (House bill not yet introduced). The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process. S.3209, the Safe Chemicals Act of 2010 (House bill not yet introduced). The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process. S.3209, the Safe Chemicals Act of 2010 (House bill not yet introduced). The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process. S.3209, the Safe Chemicals Act of 2010 (House bill not yet introduced). The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process. S.3209, the Safe Chemicals Act of 2010 (House bill not yet introduced). The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.

Legislation in the 111th HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523. House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC. Future Legislative Proposals The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with Congresswoman Slaughters office to propose revisions to a bill previously introduced in the 110th as HR 5809, the Environmental Hormone Disruption Act (no Senate version). This bill would authorize the director of the National Institute of Environmental Health Sciences (NIEHS) to establish a comprehensive program to better understand the impact of hormone disrupting pollutants in the environment on the health of women and children. The Breast Cancer Fund supports this legislation because of the need for more research on the links between environmental hazards and health. The Breast Cancer Fund supports reform of the Toxic Substances Control Act. Senator Lautenberg is currently revising a version of his legislation from the 110th, S.3040 Kid-Safe Chemicals Act, and The Breast Cancer Fund has joined with other advocates to review draft language. The bill would amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances. Regulation and Legislative Intent In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC. Future Legislative Proposals The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523. House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC. Future Legislative Proposals The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetis legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523. House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC. Future Legislative Proposals The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with Congresswoman Slaughters office to propose revisions to a bill previously introduced in the 110th as HR 5809, the Environmental Hormone Disruption Act (no Senate version). This bill would authorize the director of the National Institute of Environmental Health Sciences (NIEHS) to establish a comprehensive program to better understand the impact of hormone disrupting pollutants in the environment on the health of women and children. The Breast Cancer Fund supports this legislation because of the need for more research on the links between environmental hazards and health. The Breast Cancer Fund supports reform of the Toxic Substances Control Act. Senator Lautenberg is currently revising a version of his legislation from the 110th, S.3040 Kid-Safe Chemicals Act, and The Breast Cancer Fund has joined with other advocates to review draft language. The bill would amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances. Regulation and Legislative Intent In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523. House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC. Future Legislative Proposals The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with Congresswoman Slaughters office to propose revisions to a bill previously introduced in the 110th as HR 5809, the Environmental Hormone Disruption Act (no Senate version). This bill would authorize the director of the National Institute of Environmental Health Sciences (NIEHS) to establish a comprehensive program to better understand the impact of hormone disrupting pollutants in the environment on the health of women and children. The Breast Cancer Fund supports this legislation because of the need for more research on the links between environmental hazards and health. The Breast Cancer Fund supports reform of the Toxic Substances Control Act. Senator Lautenberg is currently revising a version of his legislation from the 110th, S.3040 Kid-Safe Chemicals Act, and The Breast Cancer Fund has joined with other advocates to review draft language. The bill would amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances. Regulation and Legislative Intent In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523. House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC. Future Legislative Proposals The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with Congresswoman Slaughters office to propose revisions to a bill previously introduced in the 110th as HR 5809, the Environmental Hormone Disruption Act (no Senate version). This bill would authorize the director of the National Institute of Environmental Health Sciences (NIEHS) to establish a comprehensive program to better understand the impact of hormone disrupting pollutants in the environment on the health of women and children. The Breast Cancer Fund supports this legislation because of the need for more research on the links between environmental hazards and health. The Breast Cancer Fund supports reform of the Toxic Substances Control Act. Senator Lautenberg is currently revising a version of his legislation from the 110th, S.3040 Kid-Safe Chemicals Act, and The Breast Cancer Fund has joined with other advocates to review draft language. The bill would amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances. Regulation and Legislative Intent In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523. House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC. Future Legislative Proposals The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetis legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC. Future Legislative Proposals The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523. House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC. Future Legislative Proposals The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with Congresswoman Slaughters office to propose revisions to a bill previously introduced in the 110th as HR 5809, the Environmental Hormone Disruption Act (no Senate version). This bill would authorize the director of the National Institute of Environmental Health Sciences (NIEHS) to establish a comprehensive program to better understand the impact of hormone disrupting pollutants in the environment on the health of women and children. The Breast Cancer Fund supports this legislation because of the need for more research on the links between environmental hazards and health. The Breast Cancer Fund supports reform of the Toxic Substances Control Act. Senator Lautenberg is currently revising a version of his legislation from the 110th, S.3040 Kid-Safe Chemicals Act, and The Breast Cancer Fund has joined with other advocates to review draft language. The bill would amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances. Regulation and Legislative Intent In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Legislation in the 111th HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523. House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC. Future Legislative Proposals The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetis legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Deceptive Practices and Voter Intimidation Prevention Act of 2007[H.R.1281, S. 453) and general voting rights issues

Deceptive Practices and Voter Intimidation Prevention Act of 2007[H.R.1281, S. 453) and general voting rights issues

Voter Intimidation Prevention Act of 2007[H.R.1281, S. 453) and general voting rights issues

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys. House Labor, HHS Appropriations bill for Biomonitoring and Health Tracking for Fiscal year 2009.

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys.

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys. House Labor, HHS Appropriations bill for Biomonitoring and Health Tracking for Fiscal year 2009.

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys.

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys.

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys. House Labor, HHS Appropriations bill for Biomonitoring and Health Tracking for Fiscal year 2009.

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys.

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys. House Labor, HHS Appropriations bill for Biomonitoring and Health Tracking for Fiscal year 2009.

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys. House Labor, HHS Appropriations bill for Biomonitoring and Health Tracking for Fiscal year 2009.

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys.

Deceptive Practices and Voter Intimidation Prevention Act of 2007[H.R.1281, S. 453) and general voting rights issues

Voter Intimidation Prevention Act of 2007[H.R.1281, S. 453) and general voting rights issues

Deceptive Practices and Voter Intimidation Prevention Act of 2007[H.R.1281, S. 453) and general voting rights issues

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys. House Labor, HHS Appropriations bill for Biomonitoring and Health Tracking for Fiscal year 2009.

H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007 This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer. S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products. S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys.